Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
| Autor: | Sohaib Al-Asaaed, Eric Winquist |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Adenocarcinoma Prostate cancer Prostate Internal medicine medicine Humans Clinical Trials as Topic Clusterin biology business.industry Prostatic Neoplasms Cancer Thionucleotides medicine.disease Radiation therapy medicine.anatomical_structure Localized disease Cancer cell biology.protein business |
| Zdroj: | Current Oncology Reports. 15:113-118 |
| ISSN: | 1534-6269 1523-3790 |
| DOI: | 10.1007/s11912-012-0285-1 |
| Popis: | Adenocarcinoma of the prostate is the most common cancer in men in the Western Hemisphere. This diagnosis includes a clinicopathologically diverse collection of disease entities, encompassing a spectrum from early localized disease to advanced-stage castration-sensitive and ultimately metastatic, castration-resistant states. Although early-stage disease is treatable and potentially curable, treatment options for castration-resistant prostate cancer, the common pathway to prostate cancer death, remain limited and palliative in nature. Therapeutic resistance to androgen blockade, cytotoxic chemotherapy, and radiotherapy is underpinned by a number of cellular mechanisms. The upregulation of protective, antiapoptotic chaperone proteins is one of these mechanisms, and is exemplified by the protein clusterin in castration-resistant prostate cancer. Antisense oligonucleotide technology provides the potential to inhibit specific genes in cancer cells and with this the possibility of a vast impact in oncology, but no antisense drugs have been approved for use in cancer patients to date. Custirsen (OGX-011) is a novel antisense oligonucleotide drug which targets clusterin expression, and its application in prostate cancer is reviewed in this article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink